Candel Therapeutics Inc (NASDAQ: CADL) is 12.30% higher on its value in year-to-date trading and has touched a low of $3.79 and a high of $14.60 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The CADL stock was last observed hovering at around $6.25 in the last trading session, with the day’s gains setting it 0.6%.
Currently trading at $6.85, the stock is 28.37% and 27.45% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.52 million and changing 9.60% at the moment leaves the stock 7.76% off its SMA200. CADL registered -21.08% loss for a year compared to 6-month loss of -11.84%. The firm has a 50-day simple moving average (SMA 50) of $5.3159 and a 200-day simple moving average (SMA200) of $6.361375.
The stock witnessed a 33.53% gain in the last 1 month and extending the period to 3 months gives it a 32.50%, and is 12.48% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.67% over the week and 6.98% over the month.
Candel Therapeutics Inc (CADL) has around 38 employees, a market worth around $365.27M and $0.00M in sales. Distance from 52-week low is 80.98% and -53.08% from its 52-week high. The company has generated returns on investments over the last 12 months (-52.19%).
The EPS is expected to grow by 72.53% this year
114.0 institutions hold shares in Candel Therapeutics Inc (CADL), with institutional investors hold 49.38% of the company’s shares. The shares outstanding are 49.25M, and float is at 36.70M with Short Float at 17.93%. Institutions hold 40.72% of the Float.
The top institutional shareholder in the company is NORTHPOND VENTURES, LLC with over 1.94 million shares valued at $12.0 million. The investor’s holdings represent 6.477 of the CADL Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 0.82 million shares valued at $5.1 million to account for 2.7548 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 0.82 million shares representing 2.7396 and valued at over $5.08 million, while STATE STREET CORP holds 1.5824 of the shares totaling 0.47 million with a market value of $2.93 million.
Candel Therapeutics Inc (CADL) Insider Activity
The most recent transaction is an insider sale by Nichols William Garrett, the company’s Chief Medical Officer. SEC filings show that Nichols William Garrett sold 781 shares of the company’s common stock on Jun 30 ’25 at a price of $5.04 per share for a total of $3936.0. Following the sale, the insider now owns 52493.0 shares.
Still, SEC filings show that on Mar 18 ’25, Nichols William Garrett (Chief Medical Officer) disposed off 45,316 shares at an average price of $8.76 for $0.4 million. The insider now directly holds 52,493 shares of Candel Therapeutics Inc (CADL).
